Zoledronic acid - Generic Drug Details

What are the generic sources for zoledronic acid and what is the scope of patent protection?

Zoledronic acid is the generic ingredient in four branded drugs marketed by Sandoz, Gland, Accord Hlthcare, Actavis Inc, Amneal, Apotex, Avet Lifesciences, Bpi Labs, Breckenridge, Chartwell Rx, Dr Reddys, Dr Reddys Labs Ltd, Epic Pharma Llc, Eugia Pharma, Fresenius Kabi Usa, Hikma Farmaceutica, Hospira, Hospira Inc, Inforlife, Meitheal, Mylan Labs Ltd, Novast Labs, Sagent Pharms Inc, Shilpa, Sun Pharma Global, USV, and Novartis, and is included in forty NDAs. There are three patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Zoledronic acid has thirty-nine patent family members in twenty-four countries.

There are twenty-five drug master file entries for zoledronic acid. Twenty-two suppliers are listed for this compound. There are eleven tentative approvals for this compound.

Summary for zoledronic acid

International Patents:	39
US Patents:	3
Tradenames:	4
Applicants:	27
NDAs:	40
Drug Master File Entries:	25
Finished Product Suppliers / Packagers:	22
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	300
Patent Applications:	5,661
Drug Prices:	Drug price trends for zoledronic acid
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for zoledronic acid
What excipients (inactive ingredients) are in zoledronic acid?	zoledronic acid excipients list
DailyMed Link:	zoledronic acid at DailyMed

See drug prices for zoledronic acid

Recent Clinical Trials for zoledronic acid

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Florida	PHASE1
Beckwith Foundation	PHASE2
Amgen	PHASE2

See all zoledronic acid clinical trials

Generic filers with tentative approvals for ZOLEDRONIC ACID

Applicant	Application No.	Strength	Dosage Form
		4MG/5ML(0.8MG/ML)	INJECTABLE;INJECTION
		EQ 4MG BASE/5ML	INJECTABLE; IV (INFUSION)
		EQ 4MG BASE/VIAL	INJECTABLE; IV (INFUSION)

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for zoledronic acid

Drug Class

Bisphosphonate

Anatomical Therapeutic Chemical (ATC) Classes for zoledronic acid

M05BA	Bisphosphonates
M05B	DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
M05	DRUGS FOR TREATMENT OF BONE DISEASES
M	Musculo-skeletal system

Paragraph IV (Patent) Challenges for ZOLEDRONIC ACID

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZOMETA	Injection	zoledronic acid	4 mg/100 mL, 100 mL vial	021223	1	2012-01-31
RECLAST	Injection	zoledronic acid	0.05 mg/mL, 100 mL vial	021817	1	2008-08-29
ZOMETA	Injection	zoledronic acid	0.8 mg (base) /mL	021223	1	2008-06-11

US Patents and Regulatory Information for zoledronic acid

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys	ZOLEDRONIC ACID	zoledronic acid	INJECTABLE;INTRAVENOUS	204344-001	Nov 19, 2018		DISCN	No	No
Dr Reddys Labs Ltd	ZOLEDRONIC ACID	zoledronic acid	INJECTABLE;INTRAVENOUS	091363-001	Mar 29, 2013	AP	RX	No	No
Hikma Farmaceutica	ZOLEDRONIC ACID	zoledronic acid	INJECTABLE;INTRAVENOUS	202182-001	Jun 3, 2013	AP	RX	No	No
Chartwell Rx	ZOLEDRONIC ACID	zoledronic acid	INJECTABLE;INTRAVENOUS	202571-001	May 7, 2013	AP	RX	No	No
Hospira Inc	ZOLEDRONIC ACID	zoledronic acid	INJECTABLE;INTRAVENOUS	202837-001	Apr 5, 2013	AP	RX	No	No
Hospira	ZOLEDRONIC ACID	zoledronic acid	SOLUTION;INTRAVENOUS	204016-001	Dec 28, 2015		DISCN	No	No
Avet Lifesciences	ZOLEDRONIC ACID	zoledronic acid	INJECTABLE;INTRAVENOUS	201801-001	Mar 29, 2013		DISCN	No	No

Expired US Patents for zoledronic acid

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-002	Mar 7, 2003
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-003	Jun 17, 2011
Sandoz	RECLAST	zoledronic acid	INJECTABLE;INTRAVENOUS	021817-001	Apr 16, 2007
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-002	Mar 7, 2003
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-002	Mar 7, 2003
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-001	Aug 20, 2001
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-001	Aug 20, 2001

EU/EMA Drug Approvals for zoledronic acid

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Accord Healthcare S.L.U.	Zoledronic Acid Accord	zoledronic acid	EMEA/H/C/002667Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia (TIH).	Authorised	yes	no	no	2014-01-16
Actavis Group PTC ehf	Zoledronic acid Actavis	zoledronic acid	EMEA/H/C/002488Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia.	Authorised	yes	no	no	2012-04-20
Mylan Pharmaceuticals Limited	Zoledronic acid Mylan	zoledronic acid	EMEA/H/C/002482Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone;treatment of adult patients with tumour-induced hypercalcaemia (TIH).	Authorised	yes	no	no	2012-08-23
Pfizer Europe MA EEIG	Zoledronic Acid Hospira	zoledronic acid	EMEA/H/C/0023654 mg / 5 ml and 4 mg / 100 ml:Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia (TIH).5 mg / 100 ml:Treatment of osteoporosis:in post-menopausal women;in men;at increased risk of fracture, including those with a recent low-trauma hip fracture.Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy:in post-menopausal women;in men;at increased risk of fracture.Treatment of Paget's disease of the bone in adults.	Authorised	yes	no	no	2012-11-19
Teva B.V.	Zoledronic acid Teva	zoledronic acid	EMEA/H/C/002439Prevention of skeletal-related events and treatment of tumour-induced hypercalcaemia.	Authorised	yes	no	no	2012-08-16
Sandoz Pharmaceuticals d.d.	Aclasta	zoledronic acid	EMEA/H/C/000595Treatment of osteoporosis:, , , in post-menopausal women;, in men;, , , at increased risk of fracture, including those with a recent low-trauma hip fracture., , Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture., , Treatment of Paget's disease of the bone.,	Authorised	no	no	no	2005-04-15
Phoenix Labs Unlimited Company	Zometa	zoledronic acid	EMEA/H/C/000336Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone;treatment of tumour-induced hypercalcaemia (TIH);prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone;treatment of tumour-induced hypercalcaemia (TIH);prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone;treatment of adult patients with tumour-induced hypercalcaemia (TIH).	Authorised	no	no	no	2001-03-20

International Patents for zoledronic acid

Country	Patent Number	Title	Estimated Expiration
Japan	2007505861
South Korea	101015718
Tunisia	SN06084	PHARMACEUTICAL PRODUCTS COMPRISING BISPHOSPHONATES
Israel	173766	PHARMACEUTICAL PRODUCT COMPRISING A READY TO USE ZOLEDRONIC ACID SOLUTION AND PROCESS FOR ITS PRODUCTION
Taiwan	I345977
Japan	2013151553	USE OF ZOLENDRONATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF BONE METABOLISM DISEASES
Colombia	5680461	PRODUCTOS FARMACEUTICOS QUE COMPRENDEN BISFOSFONATOS

Supplementary Protection Certificates for zoledronic acid

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0258618	SPC/GB01/042	United Kingdom		PRODUCT NAME: ZOLEDRONIC ACID 2-(IMIDAZOL-1-YL)-1-HYDROXYETHANE-1,1-DIPHOSPHONIC ACID; REGISTERED: CH 55463 20001128; UK EU/1/01/176/001 20010320; UK EU/1/01/176/002 20010320; UK EU/1/01/176/003 20010320
0275821	01C0035	France		PRODUCT NAME: ZOLEDRONIC ACID; NAT REG. NO/DATE: EU/1/01/176/001 20010320; FIRST REG.: LI IKS N 55 463 20001128
0275821	SPC/GB01/039	United Kingdom		PRODUCT NAME: ZOLEDRONIC ACID OPTIONALLY IN THE FORM OF A SALT THEREOF; NATIONAL REGISTRATION NO/DATE: EU/1/01/176/001-003 20010320; FIRST REGISTRATION: CH 55463 20001128
1591122	132013902140458	Italy		PRODUCT NAME: ACIDO ZOLEDRONICO(ACLASTA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/05/308/002, 20071003;57363, 20070927

Market Dynamics and Financial Trajectory for Zoledronic Acid

Last updated: July 27, 2025

Introduction

Zoledronic acid, a potent nitrogen-containing bisphosphonate, is widely utilized in the management of various bone disorders, mainly osteoporosis, Paget’s disease, and bone metastases associated with cancers such as breast, prostate, and multiple myeloma. Since its FDA approval in 2001, zoledronic acid has established a substantial presence within the global pharmaceutical landscape. This report delineates the market dynamics and financial trajectory influencing zoledronic acid, providing insights into factors shaping its growth, challenges, and future prospects.

Market Overview

Product Profile and Therapeutic Indications

Zoledronic acid’s primary mechanism involves inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway. Its efficacy in reducing skeletal-related events (SREs) in cancer patients and increasing bone mineral density (BMD) in osteoporosis has driven widespread application [1].

Initial markets centered on oncology-related indications. Over time, the expansion into osteoporosis management, especially among postmenopausal women and elderly populations, broadened its commercial footprint. Notable branded formulations include Zometa (oncology) and Reclast (osteoporosis), with generic versions entering markets post-patent expiry.

Market Size and Growth Trends

The global zoledronic acid market was valued at approximately USD 1.2 billion in 2022, with a compound annual growth rate (CAGR) projected at about 4.8% from 2023 to 2030 [2]. The escalation is driven by an aging population globally, increasing prevalence of osteoporosis, and rising cancer incidence rates.

Regionally, North America commands the largest market share due to extensive healthcare infrastructure, high awareness, and reimbursement policies. Europe follows suit, while Asia-Pacific emerges as a high-growth territory, supported by increasing healthcare access and disease prevalence.

Competitive Landscape

The market is characterized by a mix of established players—such as Novartis, Teva Pharmaceutical Industries, and Mylan—and emerging generic manufacturers. Patent expirations have catalyzed a wave of generics, significantly influencing pricing dynamics and market accessibility.

Market Dynamics

Driving Factors

• Aging Population: The demographic trend toward an older population increases osteoporosis and cancer-related skeletal complications, boosting demand for zoledronic acid [3].
• Rising Cancer Incidences: The prevalence of breast, prostate, and multiple myeloma enhances use of zoledronic acid to manage bone metastases, reducing SREs.
• Clinical Efficacy and Extended Indications: Robust clinical trials demonstrating safety and efficacy bolster clinician confidence and expand approved therapeutic uses.
• Reimbursement Policies: Favorable reimbursement frameworks in developed countries promote utilization.

Restraints and Challenges

• Safety Concerns: Rare but severe adverse effects, notably osteonecrosis of the jaw (ONJ) and atypical femur fractures, have prompted caution, influencing prescription patterns.
• Pricing Pressures and Generic Competition: Post-patent expiry, generic versions have led to substantial price reductions, squeezing profit margins for brand manufacturers.
• Alternative Therapies: The emergence of newer agents like denosumab, a monoclonal antibody inhibiting osteoclast formation, presents substitutes in several indications.
• Regulatory and Reimbursement Variability: Divergences across regions impact market access and adoption rates.

Regulatory and Policy Influences

Regulatory bodies have implemented evolving guidance on safety monitoring and reporting side effects, impacting formulary decisions. Reimbursement policies focusing on cost-effective care further influence market dynamics.

Financial Trajectory

Revenue Trends and Forecasts

Revenues from zoledronic acid have experienced a peak phase driven by branded product sales, followed by a plateau and recent decline as generic versions permeate the market. For example, Novartis’ Zometa generated peak revenues of USD 400–500 million annually before generic entrants emerged [4].

Forecasts suggest a declining trend for branded formulations, with total global revenues stabilizing around USD 800 million–USD 1 billion by 2030, largely buoyed by growth in emerging markets and new indications.

Impact of Patent Expirations

The expiration of key patents (notably in the early 2010s) opened the market to generics, reducing prices by up to 70% in some regions. This shift led to a redistribution of revenue streams from patent-holding companies to generic manufacturers.

Emerging Markets and Expansion Strategies

Pharmaceutical companies are increasingly focusing on markets in Asia-Pacific and Latin America, where growing healthcare infrastructure and increasing disease burden facilitate higher penetration. Local manufacturing, pricing strategies, and partnerships are vital to capturing these markets.

Future Outlook

Market Growth Opportunities

• Bone Health in Oncology: Expanding use in early metastatic settings with combination therapies.
• Osteoporosis in Special Populations: Addressing osteoporosis among men and premenopausal women.
• Innovative Formulations: Development of less invasive, longer-acting formulations or biosimilars to improve adherence and reduce costs.
• Real-World Evidence (RWE): Leveraging RWE to demonstrate long-term safety and cost-effectiveness can influence formulary decisions and reimbursement policies.

Challenges to Overcome

• Safety management remains critical; enhanced post-marketing surveillance is necessary.
• Competitive positioning against denosumab necessitates differentiation based on efficacy, safety profile, and cost considerations.
• Market saturation in mature economies requires diversification into new indications and markets.

Key Takeaways

• The zoledronic acid market is mature within developed countries but exhibits high growth potential in emerging regions driven by demographic and epidemiological factors.
• Patent expiries have dramatically transformed the competitive landscape, favoring generics and necessitating strategic innovation.
• Safety concerns, especially ONJ, influence prescribing patterns; ongoing surveillance and patient education are essential.
• Market expansion hinges on strategic entry into new indications, formulations, and geographic zones, particularly within oncology and osteoporosis among under-served populations.
• Collaboration with healthcare payers, physicians, and patient advocacy groups will be crucial in shaping the drug's financial trajectory moving forward.

---

FAQs

1. What factors primarily influence the price decline of zoledronic acid post-patent expiry?
   Patent expiries open the market to generic manufacturers, significantly increasing competition. This results in substantial price reductions—sometimes up to 70%—due to intensified price competition and increased supply, making the drug more accessible and reducing revenue for original patent holders.

2. How does zoledronic acid compare to newer therapies like denosumab?
   While zoledronic acid effectively manages SREs and osteoporosis, denosumab offers similar benefits with some advantages, such as less renal toxicity and administration options; however, it can be more expensive, and safety profiles differ. The choice depends on patient-specific factors and healthcare system preferences.

3. What safety concerns are associated with zoledronic acid?
   The most significant risks include osteonecrosis of the jaw and atypical femur fractures. These rare but severe adverse effects necessitate monitoring, dental assessments prior to therapy, and patient education to mitigate risks.

4. What is the outlook for zoledronic acid's market growth in Asia-Pacific?
   The Asia-Pacific region shows promising growth driven by rising osteoporosis and cancer rates, increasing healthcare expenditure, and greater healthcare access. Local manufacturing and tailored pricing strategies will be pivotal for market penetration.

5. Are there any ongoing developments or future innovations associated with zoledronic acid?
   Researchers are exploring formulations with extended duration, biosimilars to reduce costs, and combination therapies. Additionally, better safety profiles and real-world effectiveness data could enhance market competitiveness.

---

References

[1] Rosenberg, J., & Mankin, H. (2014). Mechanisms of bisphosphonate action in bone. Clinical Reviews in Bone and Mineral Metabolism, 12(3), 160-171.

[2] MarketsandMarkets. (2022). Zoledronic acid market forecast.

[3] WHO. (2021). Global Ageing and Health.

[4] Novartis Annual Reports. (2010-2020). Zometa revenue data.

---

Note: Figures cited are approximate and based on market research reports; actual data may vary.